After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14.
News Alert: CMS considers covering TAVR in asymptomatic patients
| |||||||||||||||||||||
| |||||||||||||||||||||


